Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H22FN3O3 |
Molecular Weight | 395.4268 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2
InChI
InChIKey=FPCCSQOGAWCVBH-UHFFFAOYSA-N
InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
Molecular Formula | C22H22FN3O3 |
Molecular Weight | 395.4268 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17147663
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17147663
Ketanserin is a selective 5HT2A receptor antagonist which was initially developed as an anti-hypertensive medicine. However, now the drug is available as a topical gel formulation for the treatment of wounds, burns, ulcers and anal fissure (Sufrexal brand name). The drug action is explained by its ability to accelerate epithelialization.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12569067 |
2.7 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Sufrexal Approved UseNon-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure |
|||
Curative | Sufrexal Approved UseNon-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure |
|||
Curative | Sufrexal Approved UseNon-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure |
|||
Curative | Sufrexal Approved UseNon-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure |
|||
Curative | Sufrexal Approved UseNon-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
193 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6617728/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
110.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
127 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
60.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
46.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
14.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
71.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
198 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
287 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
385.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/ |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
392.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
632 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
637 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
855 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
265 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
279 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
625 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
992 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6617728/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6617728/ |
0.15 mg/kg bw single, intravenous dose: 0.15 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/ |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
18.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
28 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
40 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
KETANSERIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
16.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
17.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
16.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6617728/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6617728/ |
0.15 mg/kg bw single, intravenous dose: 0.15 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.36% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/ |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
KETANSERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/ |
KETANSERIN plasma | Homo sapiens |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg single, intraarterial Highest studied dose Dose: 10 mg Route: intraarterial Route: single Dose: 10 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
10 mg single, intravenous Highest studied dose Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Sedation, Dizziness... |
60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Fainting, Dizziness... AEs leading to discontinuation/dose reduction: Fainting (10%) Sources: Dizziness (10%) Fall (20%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 44% | 10 mg single, intravenous Highest studied dose Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Sedation | 44% | 10 mg single, intravenous Highest studied dose Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Dizziness | 10% Disc. AE |
60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Fainting | 10% Disc. AE |
60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Fall | 20% Disc. AE |
60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Gastroprokinetic effect and mechanism of SK-896, a new motilin analogue, during the interdigestive period in conscious dogs. | 2001 |
|
Effect of fluvoxamine and N-methyl-D-aspartate receptor antagonists on shock-induced depression in mice. | 2001 Apr |
|
Comparison of [(18)F]altanserin and [(18)F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: pharmacological studies. | 2001 Apr |
|
Use of topical ketanserin for the treatment of ulcers in leprosy patients. | 2001 Apr-Jun |
|
Blood pressure patterns in pregnant patients on oral ketanserin. | 2001 Apr-May |
|
Role of prostanoids and endothelins in the prevention of cyclosporine-induced nephrotoxicity. | 2001 Apr-May |
|
Disturbance of serotonin 5HT2 receptors in remitted patients suffering from hereditary depressive disorder. | 2001 Aug |
|
In vivo evaluation of 4-[123I]iodo-N-[2[4-(6-trifluoromethyl-2-pyridinyl)-1-piperazinyl]ethyl]benzamide, a potential SPECT radioligand for the 5-HT1A receptor. | 2001 Aug |
|
Complex interaction of ergovaline with 5-HT2A, 5-HT1B/1D, and alpha1 receptors in isolated arteries of rat and guinea pig. | 2001 Aug |
|
Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. | 2001 Aug |
|
5-HT1A receptor-mediated activation of G-protein-gated inwardly rectifying K+ current in rat periaqueductal gray neurons. | 2001 Aug |
|
Blockade of D1 dopamine receptors in the ventral tegmental area decreases cocaine reward: possible role for dendritically released dopamine. | 2001 Aug 1 |
|
Catecholamines inhibit lipid peroxidation in young, aged, and Alzheimer's disease brain. | 2001 Aug 1 |
|
Activation of spinal serotonin(2A/2C) receptors augments nociceptive responses in the rat. | 2001 Aug 10 |
|
Serotonin 2A receptor regulation of striatal neuropeptide gene expression is selective for tachykinin, but not enkephalin neurons following dopamine depletion. | 2001 Aug 15 |
|
Role of 5-HT(2) receptor subtypes in depletion of 5-HT induced by p-chloroamphetamine in the mouse frontal cortex. | 2001 Aug 24 |
|
Serotonin(2) receptors mediate respiratory recovery after cervical spinal cord hemisection in adult rats. | 2001 Dec |
|
Influence of serotonin on the glutamate-induced excitations of secondary vestibular neurons in the rat. | 2001 Dec |
|
Inhibitory presynaptic 5-hydroxytryptamine(2A) receptors regulate evoked glutamate release from rat cerebellar mossy fibers. | 2001 Dec |
|
Activation of nicotinic receptors on GABAergic amacrine cells in the rabbit retina indirectly stimulates dopamine release. | 2001 Jan-Feb |
|
Researching the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man. | 2001 Jul |
|
Synthesis and 5-HT2A antagonist activity of derivatives of the novel heterocycles indolo[3,2-d]pyrrolo[3,2-g]azecine and benzo[d]pyrrolo[3,2-g]azecine compared to the benz[d]indolo[2,3-g]azecine derivative LE 300. | 2001 Jul |
|
Effects of 5-HT2 and 5-HT3 receptors on the modulation of nociceptive transmission in rat spinal cord according to the formalin test. | 2001 Jul 13 |
|
Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. | 2001 Jul-Aug |
|
The effects of hypothyroidism on 5-HT1A and 5-HT2A receptors and the serotonin transporter protein in the rat brain. | 2001 Jul-Aug |
|
Platelet 3H ketanserin binding in migraine. | 2001 Jun |
|
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. | 2001 Jun |
|
The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution. | 2001 Jun |
|
Effect of bile salts on colonic mucus secretion in isolated vascularly perfused rat colon. | 2001 Jun |
|
Pharmacological evaluation of (+)-2- [123I]A-69024: a radioligand for in vivo studies of dopamine D1 receptors. | 2001 Jun 29 |
|
Could the 5-HT1B receptor inverse agonism affect learning consolidation? | 2001 Mar |
|
Conditioned antinociception and freezing using electrical stimulation of the dorsal periaqueductal gray or inferior colliculus as unconditioned stimulus are differentially regulated by 5-HT2A receptors in rats. | 2001 May |
|
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. | 2001 May 18 |
|
Antidepressant-like effects of aniracetam in aged rats and its mode of action. | 2001 Nov |
|
Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia. | 2001 Nov |
|
Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries. | 2001 Nov 6 |
|
Binding affinity of a newly synthesized 5-HT2 antagonist, AT-1015 (N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-piperidino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate), in the rabbit platelet membrane. | 2001 Oct |
|
Enhanced contraction to 5-hydroxytryptamine is not due to "unmasking" of 5-hydroxytryptamine(1b) receptors in the mesenteric artery of the deoxycorticosterone acetate-salt rat. | 2001 Oct |
|
Physiology and pathophysiology of the serotonergic system and its implications on mental and physical performance. Part II. | 2001 Oct |
|
Activation of Erk mitogen-activated protein kinase proteins by vascular serotonin receptors. | 2001 Oct |
|
Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists. | 2001 Oct |
|
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. | 2001 Oct |
|
Neuroepithelial bodies in mammalian lung express functional serotonin type 3 receptor. | 2001 Oct |
|
Ketanserin attenuates the behavioural effects of corticosterone: implications for 5-HT(2A) receptor regulation. | 2001 Oct 5 |
|
Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743. | 2001 Oct 5 |
|
On the role of serotonin2A/2C receptors in the sensitization to cocaine. | 2001 Sep |
|
Prostaglandins may participate in opioidergic and cholinergic control of the diurnal changes of tuberoinfundibular dopaminergic neuronal activity and serum prolactin level in ovariectomized, estrogen-treated rats. | 2001 Sep 1 |
|
Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. | 2001 Sep 1 |
|
Stimulation of 5-HT2 receptors in the nucleus tractus solitarius enhances NMDA receptor-mediated reflex-evoked bradycardiac responses in the rat. | 2001 Sep 17 |
|
Effects of 5-HT(2) receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test with mice. | 2001 Sep 21 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17147663
Apply a thin layer twice a day (topical gel) or use one applicator every 24 hours at night before bed for two weeks (vaginal application). In case of anal fissure, apply a small amount of the gel digitally in the anus area 3 times a day, preferably after bowel movement and cleaning the area with soap and water. The minimum recommended treatment time is 15 days.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17147663
2% and 20% topical ketanserin significantly accelerates both the vascular epithelial rates of wound healing in full-thickness nonpathologic skin wounds.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:48:17 GMT 2025
by
admin
on
Wed Apr 02 09:48:17 GMT 2025
|
Record UNII |
97F9DE4CT4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QD03AX90
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
||
|
WHO-ATC |
C02KD01
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
||
|
NCI_THESAURUS |
C66885
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
||
|
WHO-VATC |
QC02KD01
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
88
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
277-680-2
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
1524
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
C604
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
DB12465
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL51
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
6123
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
100000082848
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
5087
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
D007650
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
KETANSERIN
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
97F9DE4CT4
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
m6614
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID3023188
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
SUB08366MIG
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
74050-98-9
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
3822
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | |||
|
6131
Created by
admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
LABELED -> NON-LABELED |
|
||
|
TARGET -> INHIBITOR |
Binding Assay
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
OFF-TARGET->INHIBITOR |
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|